Royalty Pharma plc
RPRX
$53.25
$1.553.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 827.29M | 771.95M | 765.96M | 1.02B | 1.09B |
| Total Depreciation and Amortization | 5.02M | 3.85M | 2.66M | 1.38M | -- |
| Total Amortization of Deferred Charges | 31.03M | 28.64M | 26.40M | 23.91M | 20.49M |
| Total Other Non-Cash Items | -1.66B | -1.65B | -1.59B | -1.78B | -1.50B |
| Change in Net Operating Assets | 3.41B | 3.34B | 3.20B | 3.14B | 3.09B |
| Cash from Operations | 2.61B | 2.49B | 2.41B | 2.41B | 2.70B |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -74.42M | -74.42M | -74.42M | -74.19M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.52B | -1.54B | -1.20B | -1.43B | -2.09B |
| Cash from Investing | -2.60B | -1.61B | -1.27B | -1.51B | -2.09B |
| Total Debt Issued | 3.23B | 3.23B | 3.23B | 0.00 | 1.47B |
| Total Debt Repaid | -2.28B | -2.28B | -2.28B | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -568.70M | -1.23B | -1.20B | -1.15B | -938.43M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -387.39M | -378.25M | -377.57M | -376.32M | -378.02M |
| Other Financing Activities | -515.73M | -534.81M | -521.80M | -506.26M | -522.94M |
| Cash from Financing | -517.34M | -1.19B | -1.14B | -2.03B | -368.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -501.33M | -310.33M | -11.11M | -1.13B | 244.72M |